Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...
Korea Joongang Daily on MSN13h
Olix, Eli Lilly to develop liver disease drug under $630 million dealOlix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...
A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
The request follows a similar move by Eli Lilly, which has asked for a ban on ... that it accuses of unlawfully making semaglutide. The company has claimed that compounded semaglutide with ...
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback